NR1H2 and fatty liver disease: Although activated LXRs can regulate cholesterol metabolism and reduce inflammatory effects, LXRs agonists easily cause hepatic steatosis and dyslipidemia, which hampers the further development and application of synthetic LXRs agonists [13], such as LXRβ-selective agonist.